EA201790441A1 - Антитела к il-25 и их применения - Google Patents

Антитела к il-25 и их применения

Info

Publication number
EA201790441A1
EA201790441A1 EA201790441A EA201790441A EA201790441A1 EA 201790441 A1 EA201790441 A1 EA 201790441A1 EA 201790441 A EA201790441 A EA 201790441A EA 201790441 A EA201790441 A EA 201790441A EA 201790441 A1 EA201790441 A1 EA 201790441A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
present
human
bind
accordance
Prior art date
Application number
EA201790441A
Other languages
English (en)
Other versions
EA036658B1 (ru
Inventor
Джеми М. Оренго
Джинни Эллинн
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Publication of EA201790441A1 publication Critical patent/EA201790441A1/ru
Publication of EA036658B1 publication Critical patent/EA036658B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)

Abstract

Настоящее изобретение относится к антителам, которые связываются с человеческим интерлейкином-25 (IL-25), и способам их применения. В соответствии с некоторыми вариантами осуществления антитела по настоящему изобретению связывают человеческий IL-25 с высокой аффинностью. В соответствии с некоторыми вариантами осуществления настоящее изобретение относится к антителам, которые связывают человеческий IL-25 и блокируют IL-25-опосредованную передачу клеточных сигналов. Антитела по настоящему изобретению могут быть полностью человеческими, не встречающимися в природе антителами. Антитела по настоящему изобретению могут быть пригодны для лечения различных нарушений, ассоциированных с активностью или экспрессией IL-25, в том числе астмы, аллергии, хронической обструктивной болезни легких (COPD), воспалительного заболевания кишечника (IBD), включая язвенный колит и болезнь Крона, атопического дерматита (AD) и эозинофильного гранулематоза с ангиопатией (EGPA), также известного как синдром Черджа-Стросса.
EA201790441A 2014-09-23 2015-09-22 Антитела к il-25 и их применения EA036658B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462054167P 2014-09-23 2014-09-23
PCT/US2015/051407 WO2016049000A2 (en) 2014-09-23 2015-09-22 Anti-il-25 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EA201790441A1 true EA201790441A1 (ru) 2017-08-31
EA036658B1 EA036658B1 (ru) 2020-12-04

Family

ID=54207847

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790441A EA036658B1 (ru) 2014-09-23 2015-09-22 Антитела к il-25 и их применения

Country Status (20)

Country Link
US (3) US9840557B2 (ru)
EP (1) EP3197914B1 (ru)
JP (2) JP6694877B2 (ru)
KR (1) KR102576368B1 (ru)
CN (1) CN107207589B (ru)
AU (1) AU2015321517B2 (ru)
BR (1) BR112017005692A2 (ru)
CA (1) CA2961517C (ru)
CL (2) CL2017000703A1 (ru)
CO (1) CO2017003072A2 (ru)
EA (1) EA036658B1 (ru)
IL (1) IL251001B (ru)
MA (1) MA40106A1 (ru)
MX (1) MX2017003841A (ru)
MY (1) MY185832A (ru)
NZ (1) NZ730105A (ru)
PH (1) PH12017500403A1 (ru)
SG (2) SG10201913084PA (ru)
WO (1) WO2016049000A2 (ru)
ZA (1) ZA201701663B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2961517C (en) 2014-09-23 2023-05-02 Regeneron Pharmaceuticals, Inc. Anti-il-25 antibodies and uses thereof
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
CN107213463A (zh) * 2017-05-24 2017-09-29 清华大学 白介素25在银屑病的发育中的作用
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
US20210332123A1 (en) * 2018-11-19 2021-10-28 Suzhou Kanova Biopharmaceutical Co., Ltd. Anti-il-25 antibodies and use thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
TW202241928A (zh) * 2021-01-08 2022-11-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
WO2023160610A1 (en) * 2022-02-24 2023-08-31 Sinomab Bioscience Limited Bispecific binding proteins against alarmins and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
GB0707505D0 (en) * 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) * 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
WO2011123507A1 (en) 2010-03-30 2011-10-06 Centocor Ortho Biotech Inc. Humanized il-25 antibodies
WO2012097126A2 (en) * 2011-01-13 2012-07-19 The University Of Maryland, Baltimore Il-25 treatment of obesity and metabolic disorders
US9834601B2 (en) * 2012-06-12 2017-12-05 Orega Biotech Antagonists of IL-17 isoforms and their uses
CA2961517C (en) 2014-09-23 2023-05-02 Regeneron Pharmaceuticals, Inc. Anti-il-25 antibodies and uses thereof

Also Published As

Publication number Publication date
US20160083466A1 (en) 2016-03-24
CO2017003072A2 (es) 2017-06-30
AU2015321517A1 (en) 2017-04-06
EP3197914A2 (en) 2017-08-02
SG11201701712WA (en) 2017-04-27
BR112017005692A2 (pt) 2017-12-12
MY185832A (en) 2021-06-11
KR102576368B1 (ko) 2023-09-08
WO2016049000A2 (en) 2016-03-31
US9840557B2 (en) 2017-12-12
CL2018003608A1 (es) 2019-03-15
NZ730105A (en) 2024-01-26
MA40106A1 (fr) 2018-06-29
SG10201913084PA (en) 2020-03-30
CN107207589B (zh) 2021-04-06
ZA201701663B (en) 2023-04-26
EP3197914B1 (en) 2024-02-07
WO2016049000A3 (en) 2016-05-06
IL251001B (en) 2021-04-29
US11542326B2 (en) 2023-01-03
KR20170063671A (ko) 2017-06-08
EA036658B1 (ru) 2020-12-04
US10640558B2 (en) 2020-05-05
CN107207589A (zh) 2017-09-26
JP2020075926A (ja) 2020-05-21
US20200262912A1 (en) 2020-08-20
JP6916319B2 (ja) 2021-08-11
CL2017000703A1 (es) 2017-12-29
MX2017003841A (es) 2018-02-23
CA2961517A1 (en) 2016-03-31
JP2017533888A (ja) 2017-11-16
PH12017500403A1 (en) 2017-07-17
US20180057583A1 (en) 2018-03-01
AU2015321517B2 (en) 2021-02-18
JP6694877B2 (ja) 2020-05-20
IL251001A0 (en) 2017-04-30
CA2961517C (en) 2023-05-02

Similar Documents

Publication Publication Date Title
EA201790441A1 (ru) Антитела к il-25 и их применения
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
MX2018006385A (es) Moleculas de anticuerpo contra april y usos de las mismas.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
WO2017106656A8 (en) Antibody molecules to pd-1 and uses thereof
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
PH12016500182A1 (en) Anti-activin a antibodies and uses thereof
PH12016501482A1 (en) Antibody molecules to tim-3 and uses thereof
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
EA201890756A1 (ru) Антитела, которые специфически связываются с tl1a
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201690456A1 (ru) Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
JO3785B1 (ar) أجسام مضادة لـ il-17a واستخدامها فى علاج أمراض المناعة الذاتية والأمراض الالتهابية
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
PH12016501547A1 (en) Anti-il-13/il-17 bispecific antibodies and uses thereof
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX371412B (es) ANTICUERPOS BIESPECÍFICOS QUE SE UNEN ESPECÍFICAMENTE A LOXL2 Y ccl.2, COMPOSICIONES DE LOS MISMOS, Y SU USO EN EL TRATAMIENTO DE ESCLERODERMIA.
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
EA201990978A1 (ru) Антитела против pd-1
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
IN2013MU03430A (ru)
MY186726A (en) Anti-activin a antibodies and uses thereof
EA202091757A2 (ru) Антитела к активину а и их применение